OVERALL AND SITE-SPECIFIC RISK OF MALIGNANT-MELANOMA ASSOCIATED WITH NEVUS COUNTS AT DIFFERENT BODY SITES - A MULTICENTER CASE-CONTROL STUDY OF THE GERMAN-CENTRAL-MALIGNANT-MELANOMA-REGISTRY

Citation
E. Rieger et al., OVERALL AND SITE-SPECIFIC RISK OF MALIGNANT-MELANOMA ASSOCIATED WITH NEVUS COUNTS AT DIFFERENT BODY SITES - A MULTICENTER CASE-CONTROL STUDY OF THE GERMAN-CENTRAL-MALIGNANT-MELANOMA-REGISTRY, International journal of cancer, 62(4), 1995, pp. 393-397
Citations number
22
Categorie Soggetti
Oncology
ISSN journal
00207136
Volume
62
Issue
4
Year of publication
1995
Pages
393 - 397
Database
ISI
SICI code
0020-7136(1995)62:4<393:OASROM>2.0.ZU;2-Y
Abstract
A large number of benign melanocytic nevi is the major risk factor for malignant melanoma (MM). In a multicenter case-control study, the num ber of common (CN) and clinically atypical (AN) nevi were counted sepa rately at individual sites in 278 melanoma patients and 278 age- and g ender-matched non-melanoma controls. Relative risk (RR) adjusted for a ge and sex was calculated. In men as well as women, the number of CN o n the legs was the best predictor of overall melanoma risk. In men, RR for developing MM when greater than or equal to 1 AN were present on the trunk was 4-fold (vs. none). In women, presence of AN on the arms increased RR 9.5-fold. For men and women combined, after adjusting for age and gender, the RR for developing MM on the trunk and on the legs was best predicted by counts of CN at the respective body region. How ever, high counts of CN on the arms were associated with high melanoma risk on the legs (somewhat lower on the trunk). For AN, no site-speci ficity of melanoma risk was found. Our data suggest that nevus counts of the legs are the best predictor of overall melanoma risk if total b ody nevus counts are not feasible. Although high counts of CN on the t runk and legs are associated with a higher risk of developing MM at th e respective site than at another site, our data do not unequivocally support a direct site-specific melanoma risk. (C) 1995 Wiley-Liss, Inc .